IgG levels – Page 6 – Communicable Diseases Research

Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents

회복기 아동 및 청소년의 SARS-CoV-2 면역 평가

Immunology

Published on 2021-12-172022-09-11
Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, 치료제,

Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History

BNT162b2-백신 접종 및 감염 이력에 따른 Anti-SARS-CoV-2 면역글로불린 아이소타입 및 바이러스 변이체에 대한 중화 활성

Immunology

Published on 2021-12-172022-09-11
Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, 치료기술, 치료법,

[키워드] activity Against anti-RBD Anti-RBD IgG antigen-specific antibody assays B.1 bead BNT162b2 BNT162b2 vaccine both group both groups coronavirus COVID-19 COVID-19 disease COVID‐19 cytopathic delta variant Delta variants disease domain dose expression pattern Fluorescence followed by Gamma highest history IgA IgG IgG levels IgM immunoassay Immunoglobulin immunoglobulins individual maximum mRNA vaccine multiplex immunoassay naïve neutralization Neutralization assay Neutralizing activity neutralizing capacity neutralizing titers Nucleocapsid proteins plasma post-symptom onset provided RBD Result SARS-CoV-2 SARS-CoV-2 antigen Serological assay single vaccine subject subjects suggested Support symptom onset three groups vaccination Vaccine variants Vero E6 Viral Viral antigen was determined
[DOI] 10.3389/fimmu.2021.793191 PMC 바로가기 [Article Type] Immunology

Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy

이탈리아 밀라노의 COVID-19 위탁 병원에서 의료 종사자의 BNT162b2 mRNA COVID-19 백신에 대한 항체 반응에 대한 이전 감염 상태의 영향

Article

Published on 2021-12-022022-09-11
Journal: Human vaccines & immunotherapeutics [Category] SARS, 진단, 치료기술,

[키워드] 95% CI adjusted odds ratio anti-S IgG anti-SARS-CoV-2 Antibody Response BNT162b2 BNT162b2 mRNA BNT162b2 vaccine COVID-19 COVID-19 vaccine detectable dose effective elapsed enrolled Fever first dose HCW HCWs healthcare healthcare worker Healthcare workers hospital humoral Humoral response IgG levels Impact Infection Italy Mild mild to moderate moderate mRNA vaccine naïve subjects occurred of BNT162b2 reactogenicity receive reported risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination Serious Adverse Event Serious Adverse Events serological serological response Side effect single dose spike IgG subject subjects the median the vaccine Vaccine
[DOI] 10.1080/21645515.2021.2002639 PMC 바로가기 [Article Type] Article

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals

BNT162B2- 암시 처리 된 개체에서 부작용 및 면역 동역학과의 중화/SARS-COV-2-S1- 결합 항체 반응의 상관 관계

Article

Published on 2021-11-242022-09-01
Journal: Scientific Reports [Category] MERS, SARS, 변종, 진단, 치료기술,

Antibody conversion rates to SARS-CoV-2 in saliva from children attending summer schools in Barcelona, Spain

스페인 바르셀로나에있는 여름 학교에 다니는 어린이들로부터 타액에서 SARS-COV-2 로의 항체 전환율

Research Article

Published on 2021-11-232022-09-01
Journal: BMC Medicine [Category] MERS, SARS, 변종, 진단, 치료기술, 치료법, 치료제,

[키워드] age anti-spike antibodies antibody Antibody conversion antibody profiling Antigen approach Asymptomatic Barcelona children collected contagious COVID-19 COVID-19 pandemic cross-reactive antibodies cumulative defined detect evaluated faster females FIVE Health Policies IgA IgA antibodies IgA antibody IgA level IgA levels IgG IgG level IgG levels IgM increase in individual infection rate initial isotype Luminex assay management MOST Non-invasive nucleocapsid Pandemics pediatric Population protective role public health recommendation reporting symptom required Result RT-PCR Saliva SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-COV-2 infection School Schools significantly higher Spain supplementary material symptomatic individuals variants Viral viral epidemics Viral load Viral transmission
[DOI] 10.1186/s12916-021-02184-1 PMC 바로가기 [Article Type] Research Article

Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection

감염 후 13 개월 동안 SARS-COV-2- 특이 적 항체의 지속성

Article

Published on 2021-11-192022-09-01
Journal: Viruses [Category] MERS, SARS, 진단, 치료기술,

[키워드] antibody Antibody Response Antibody responses Asymptomatic COVID-19 vaccines declined Dynamics exposure to First wave IgG IgG and IgM IgG ELISA IgG level IgG levels IgG/IgM dynamics IgM individual infected individual Infection investigated Lithuania longitudinal study majority Month outbreak pandemic Reinfection remained S protein SARS-CoV-2 SARS-CoV-2 RT-PCR SARS-CoV-2 S SARS-CoV-2 S protein SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody second wave serological monitoring serological test Serological testing seropositive individual seropositive individuals Seropositivity Severity of infection specific antibodies specific IgM virus-specific antibodies Virus-specific IgG worker
[DOI] 10.3390/v13112313 PMC 바로가기 [Article Type] Article

Detection and predictors of anti-SARS-CoV-2 antibody levels in COVID-19 patients at 8 months after symptom onset

Short Communication

Published on 2021-11-122022-10-31
Journal: Future Virology [Category] COVID-19,

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

ChAdOx1 nCoV-19 및 BNT162b2를 사용한 동종 및 이종 프라임-부스트 면역의 안전성, 반응성 및 면역원성: 전향적 코호트 연구

Observational Study

Published on 2021-11-012022-09-11
Journal: The Lancet. Respiratory Medicine [Category] MERS, SARS, 변종, 임상, 진단,

[키워드] 95% CI Alpha anti-RBD Anti-RBD IgG Anti-S1 AstraZeneca B.1.1.7 B.1.351 Berlin Beta Beta variant beta variants binding BNT162b2 boost booster Cambridge ChAdOx1 ChAdOx1 nCoV-19 Concentration COVID-19 COVID-19 vaccines Cutoff dose education enrolled geometric mean Germany health-care Heterologous heterologous prime-boost highest homologous IFN-γ IgG levels immunisation immunogenicity IMPROVE inhibitory interim analysis IQR Mainz median mitigate neutralisation test participant Pfizer-BioNTech prospective cohort study prospective observational cohort pseudovirus neutralisation assay questionnaire RBD IgG RBD-ACE2 reactivity reactogenicity receiving recipient recipients regimen reported Safety SARS-CoV-2 S1 SARS-CoV-2 virus SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody second vaccination specific antibodies supply shortage Symptom systemic systemic symptoms T-cell vaccination Vaccine variants of concern was measured
[DOI] 10.1016/S2213-2600(21)00357-X PMC 바로가기 [Article Type] Observational Study

Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia

사례 보고: 연속 사례: 인도네시아 말랑 사이풀 안와르 병원의 반복적인 COVID-19 회복기 혈장 기증자에서 높은 면역글로불린 G 수치의 연장

Case Reports

Published on 2021-11-012022-09-12
Journal: Frontiers in Immunology [Category] MERS, 진단,

Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019

중증 급성 호흡기 증후군 코로나바이러스 2 및 다중 변이체에 대한 혈청 중화 활성 코로나바이러스 질병 2019로 입원 후 6개월

Article

Published on 2021-09-152022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 진단, 치료법,

[키워드] activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Admission Against anti-S Anti-spike antibodies antibody B.1.1.7 B.1.351 B.1.351 variant characterized collected coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 correlated correlation COVID-19 D614G effective Efficiency Evolution experiment Hospitalized humoral Humoral response IgG IgG level IgG levels Immunoglobulin Immunoglobulin G initial intensive care unit intensive care units invasive ventilation Level marker Month Multiple neutralization Neutralizing activity neutralizing capacity neutralizing effect occur P.1 variant P.1 variants Patient patients hospitalized performed Postinfection Prospective Study quantified Quantitative respiratory SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sera serological Serological assay serological assays severe acute respiratory syndrome Coronavirus severity significantly sustained tested the patient variant with COVID-19
[DOI] 10.1093/cid/ciab308 PMC 바로가기 [Article Type] Article